New combo therapy shows promise for tough bone cancer

NCT ID NCT04803877

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs, regorafenib and nivolumab, can help people with osteosarcoma (a type of bone cancer) that has returned or not responded to previous treatments. About 48 participants aged 5 and older will receive the combination. The main goal is to see if this approach improves the chance of living without the cancer growing for at least 4 months, compared to historical data with regorafenib alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma pediatric osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Los Angeles

    Los Angeles, California, 90027, United States

  • Cincinnati Children's

    Cincinnati, Ohio, 45229, United States

  • Johns Hopkins

    Baltimore, Maryland, 21287, United States

  • Oregon Health and Sciences University

    Portland, Oregon, 97239, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States